A Meta-Analysis of Randomized Controlled Trials Comparing Early to Late Concurrent Thoracic Radiotherapy with Etoposide and Cisplatin/Carboplatin Chemotherapy for Limited-Disease Small Cell Lung Cancer
作者单位：Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology(Lung and Esophagus)Zhejiang Cancer Hospital
会议名称：《抗肿瘤药物研究新进展与肿瘤个性化药物治疗论坛》
会议日期：2013年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：funded by Project 81202806 supported by National Natural Science Foundation of China Zhejiang Province Medical Science Fund Project of China(No.2012KYB034 No 2012RCB004)
摘 要：[Purpose]-To clear the optimal time of concurrent thoracic radiotherapy(TRT) with etoposide and cisplatin/carboplatin(EP/EC) chemotherapy for limited-disease small cell lung cancer (LD SCLC). [Materials and methods]-Randomized controlled trials were identified according to MEDLINE,the Cochrane Central Register of Controlled Trials,EMBASE,and so on comparing early to late concurrent TRT with EP/EC chemotherapy for LD *** thoracic radiotherapy(ERT) was defined as beginning radiation within 30 days after the start of *** are three eligible randomized controlled trials. [Results]- No significance difference in objective response was detected between early concurrent TRT and late concurrent TRT(RR:1.01,95%CI 0.86-1.18,P=0.90).Similar result was detected in 1-,2-,3- and 5-year survival rates between early concurrent TRT and late concurrent TRT(RR:1.06,95%CI 0.88-1.27,P=0.56;RR:1.15,95%CI 0.77- 1.71,P=0.49;RR:0.90,95%CI 0.66-1.22,P=0.49;RR:1.18,95%CI 0.64-2.16,P= 0.60).Total grade 3-4 adverse events including anemia,leucopenia,neutropenia, thrombocytopenia,nausea and vomiting,infection,esophageal toxicity,pulmonary toxicity, alopecia and hemorrhage in early concurrent TRT were significantly higher than that in late concurrent TRT(RR:1.21,95%CI 1.03-1.43,P=0.02). [Conclusion]-The result of our work indicates that survival rate of LD-SCLC with late concurrent TRT combined EP/EC chemotherapy is similar with early concurrent TRT, while grade 3-4 adverse events were less.